Healthcare DTx: Everything you need to know about digital therapies

Introduction

The acronym "DTx" is appearing more and more frequently in discussions about innovation in healthcare. Behind these three letters lies a silent revolution that is gradually transforming medical care: digital therapies, a rapidly growing market.

These novel therapeutic solutions combine technological innovation with the scientific rigor of traditional medicine. Unlike the thousands of wellness apps available on our smartphones, DTx undergo a strict clinicaldevice evaluation process and meet the same regulatory requirements as a medical device, facilitating their access to the medical market.

This new category of treatment promises to revolutionize our approach to the prevention, treatment, and monitoring of diseases by placing the patient at the center of a personalized and connected healthcare ecosystem.

1. What is DTx?

1.1 General definition of digital therapies

Digital therapeutics (DTx) provide patients with evidence-based therapeutic interventions driven by high-quality software to treat, manage, or prevent a disorder or disease. The term "Digital Therapeutics (DTx)" specifically refers to scientifically validated treatments in the form of digital solutions (mobile applications, connected devices, etc.) to prevent and treat various conditions, with specific characteristics that distinguish them from conventional applications.

The distinction between DTx, digital health, and digital medicine is fundamental. Digital therapeutics (DTx) are clinically validated software solutions prescribed by healthcare professionals. Unlike wellness apps, DTx are digital medical devices (DMDs) designed to treat, prevent, or monitor diseases, backed by rigorous clinical evidence and precise therapeutic design.

1.2 How do these therapies work?

DTx are clinically supervised therapeutic software programs that provide personalized interventions, feedback, and follow-up to help patients change their behaviors and improve disease management. These solutions tailor therapeutic interventions based on real-time health data and continuously monitor at-risk patients to anticipate and prevent their condition from worsening by activating various therapeutic levers.

Clinicaltrials of these therapies often incorporate gamification elements to optimize patient engagement and promote treatment adherence. The therapeutic response is thus personalized thanks to intelligent algorithms that adapt to the specific needs of each user.

Concrete examples of how it works: A DTx for diabetes can analyze a patient's blood glucose data in real time and automatically adjust insulin recommendations, while a mental health solution can offer personalized therapeutic exercises based on the evolution of reported symptoms.

2. What are the benefits of DTx for patient care?

2.1 Therapeutic objectives

They are used independently or in combination with medications, devices, or other therapies to optimize patient care and health outcomes. DTx are used in four main areas: prevention, treatment, monitoring, and rehabilitation, enabling continuous and personalized therapeutic action.

A major benefit lies in empowering patients, who become actively involved in their own care thanks to personalized and accessible tools. This permanent connection between patients and the healthcare system promotes better treatment adherence and optimal monitoring of conditions.

3. For which diseases are DTx used?

Mental health: DTx show particular effectiveness in treating depression, anxiety disorders, and post-traumatic stress disorder. In July of this year, the CMS introduced a new potential reimbursement pathway for "digital mental health treatment" (DMHT) devices and services in its proposed rule for the 2025 Medicare physician fee schedule.

Chronic diseases: Digital spirometry combined with coaching has boosted asthma/COPD registrations on major platforms to 6.2 million users worldwide. DTx are particularly well developed for type 2 diabetes, hypertension, obesity, and low back pain, offering therapeutic solutions tailored to each condition.

Oncology: In oncology, DTx focus on managing side effects, including fatigue, pain, and anxiety and depression associated with cancer diagnoses. A specialised directory now specialised validated solutions in this specialty.

Rehabilitation and neurology: The Neuroventis platform consists of patient-facing applications (called Helpilepsy and MigraineManager) and a dashboard for healthcare professionals. This suite of applications offers comprehensive, integrated care. The platform is CE certified as a medical device in Europe, registered with the FDA, and currently used by more than 500 professionals and more than 20,000 patients and caregivers in more than 15 countries.

4. DTx vs. health apps: what's the difference?

The fundamental distinction lies in clinical validation and regulatory status. To date, DTx are digital therapeutic devices (when the criteria are met) that are officially recognized by health authorities.

Unlike wellness apps, which can make general health claims, DTx must demonstrate their therapeutic efficacy through rigorous clinical trials and comply with strict scientific and regulatory requirements. The quality of therapeutic content and the rigor of clinical validation are the main differences between DTx and traditional wellness apps. Accounting and reimbursement aspects are also fundamentally different between these two categories.

5. What regulations apply to DTx?

5.1 Certification and Approval

As digital medical devices (DMNs), DTx must meet European regulatory requirements, obtain CE marking, and comply with safety and performance criteria. The process includes determining the device class, implementing a compliant Quality Management System (QMS), and compiling detailed Technical Documentation. This approach requires close collaboration between technical, clinical, and regulatory teams, as well as regular consultation with the relevant authorities.

The Digital Therapeutics Alliance (DTA) is dedicated to providing patients, clinicians, payers, and policymakers with the tools they need to evaluate and use DTx products.

5.2 Concrete examples

The German example: Since 2019, it has authorized all doctors in Germany to prescribe digital therapies (Digitale Gesundheitsanwendungen, or "DiGA") to social security beneficiaries, even though clinical investigations have not been completed. The reimbursement period has been set at one year.

In France: Launched in April 2023, the digital advance coverage (PECAN) is an exceptional procedure that allows digital medical innovations to be made available to patients more quickly. Under Pecan, financial compensation for digital therapies (DTx) can reach up to €780 per patient per year.

6. GDPR compliance GDPR security: a key issue for digital therapeutics (DTx)

Digital therapies (DTx), as digital medical devices, handle health data that is considered sensitive under the GDPR General Data Protection Regulation). Compliance with this regulation is a legal requirement that cannot be ignored.

6.1 Strengthened obligations for publishers

Publishers must clearly inform users about the purposes of data processing. Consent must be explicit, free, and informed. Only data that is strictly necessary should be collected, in accordance with the principle of minimization.

Processing must be based on secure hosting certified by HDS (Health Data Hosting), and processors be governed by contractual clauses in accordance with Article 28 of GDPR.

6.2 Impact Analysis and Regulatory Framework

A privacy impact assessment ( PIA) is required when the DTx poses a high risk to the rights and freedoms of the individuals concerned. This is often the case for large-scale devices or those involving patient profiling.

6.3 User Rights and Control

Users must be able to exercise their rights of access, rectification, erasure, restriction, and portability. The CNIL (National Commission for Information Technology and Civil Liberties) exercise control and sanction any breach of the regulations.

6.4 A prerequisite for clinical deployment

Beyond the legal obligation, GDPR compliance GDPR become a selection criterion for any partnership with a healthcare institution or in the context of a reimbursement project. It also contributes to the trust of professionals and patients.

If your DTx incorporates artificial intelligence technologies, you will also need to comply with the AI Act, which regulates the use of artificial intelligence in the European Union. This regulation applies in particular to high-risk AI systems, such as those used for medical purposes, including medical diagnostic devices that incorporate AI algorithms.

Conclusion

The DTx market is a rapidly evolving sector with considerable opportunities to improve patient care, but it still faces significant challenges in terms of regulation, adoption by healthcare professionals, and integration into existing care pathways. The implementation of initiatives such as PECAN in France demonstrates a desire to accelerate patient access to these innovations while maintaining high standards of safety and efficacy.